Hoffmann La Roche Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for HOFFMANN LA ROCHE, and when can generic versions of HOFFMANN LA ROCHE drugs launch?
HOFFMANN LA ROCHE has thirteen approved drugs.
There are eleven US patents protecting HOFFMANN LA ROCHE drugs.
There are two hundred and seventy-seven patent family members on HOFFMANN LA ROCHE drugs in forty-nine countries and thirty supplementary protection certificates in seventeen countries.
Summary for Hoffmann La Roche
International Patents: | 277 |
US Patents: | 11 |
Tradenames: | 11 |
Ingredients: | 10 |
NDAs: | 13 |
Drugs and US Patents for Hoffmann La Roche
Expired US Patents for Hoffmann La Roche
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Hoffmann La Roche | BONIVA | ibandronate sodium | TABLET;ORAL | 021455-002 | Mar 24, 2005 | 6,294,196 | See Plans and Pricing |
Hoffmann La Roche | FORTOVASE | saquinavir | CAPSULE;ORAL | 020828-001 | Nov 7, 1997 | 6,008,228*PED | See Plans and Pricing |
Hoffmann La Roche | ACCUTANE | isotretinoin | CAPSULE;ORAL | 018662-003 | May 7, 1982 | 4,464,394*PED | See Plans and Pricing |
Hoffmann La Roche | ACCUTANE | isotretinoin | CAPSULE;ORAL | 018662-002 | May 7, 1982 | 4,200,647 | See Plans and Pricing |
Hoffmann La Roche | BONIVA | ibandronate sodium | TABLET;ORAL | 021455-002 | Mar 24, 2005 | 4,927,814 | See Plans and Pricing |
Hoffmann La Roche | VALCYTE | valganciclovir hydrochloride | TABLET;ORAL | 021304-001 | Mar 29, 2001 | 6,083,953*PED | See Plans and Pricing |
Hoffmann La Roche | XELODA | capecitabine | TABLET;ORAL | 020896-001 | Apr 30, 1998 | 5,472,949*PED | See Plans and Pricing |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for HOFFMANN LA ROCHE drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | For Oral Solution | 50 mg/mL | ➤ Subscribe | 2011-03-21 |
➤ Subscribe | Tablets | 2.5 mg and 150 mg | ➤ Subscribe | 2007-05-16 |
➤ Subscribe | Tablets | 450 mg | ➤ Subscribe | 2005-12-27 |
➤ Subscribe | Injection | 1 mg/mL, 3 mL Vial | ➤ Subscribe | 2007-08-31 |
➤ Subscribe | Tablets | 150 mg and 500 mg | ➤ Subscribe | 2008-11-10 |
Premature patent expirations for HOFFMANN LA ROCHE
Expiration due to failure to pay maintenance fee
Patent Number | Expiration Date |
---|---|
See Plans and Pricing | See Plans and Pricing |
International Patents for Hoffmann La Roche Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Mexico | 2012001463 | See Plans and Pricing |
European Patent Office | 3088400 | See Plans and Pricing |
Norway | 20076659 | See Plans and Pricing |
Cyprus | 1116233 | See Plans and Pricing |
Poland | 1696920 | See Plans and Pricing |
South Korea | 20130128488 | See Plans and Pricing |
European Patent Office | 2395004 | See Plans and Pricing |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Hoffmann La Roche Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0694547 | SPC/GB02/027 | United Kingdom | See Plans and Pricing | PRODUCT NAME: 2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)-METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE HYDROCHLORIDE (VALGANCICLOVIR HYDROCHLORIDE); REGISTERED: NL RVG 25992 20010920; UK PL 00031/0599 20020425 |
0316704 | 2001C/021 | Belgium | See Plans and Pricing | PRODUCT NAME: CAPECITABINE, NATL REGISTRATION NO/DATE: EU/1/00/163/001 20010205; FIRST REGISTRATION: CH 54657 19980610 |
1893612 | 132012902073472 | Italy | See Plans and Pricing | PRODUCT NAME: VEMURAFENIB(ZELBORAF); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/12/751/001, 20120221 |
0316704 | SPC/GB01/015 | United Kingdom | See Plans and Pricing | PRODUCT NAME: CAPECITABINE AND HYDRATES AND SOLVATES THEREOF; REGISTERED: CH 54657 19980610; UK EU/1/00/163/001-002 20010202 |
1893612 | 2012C/028 | Belgium | See Plans and Pricing | PRODUCT NAME: VERMURAFENIB ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, SOUS TOUTES FORMES COUVERTES PAR LE BREVET DE BASE; AUTHORISATION NUMBER AND DATE: EU/1/12/751/001 20120221 |
1893612 | C20120016 00059 | Estonia | See Plans and Pricing | PRODUCT NAME: ZELBORAF - VEMURAFENIIB;REG NO/DATE: C(2012)1180 FINAL 17.02.2012 |
1893612 | 28/2012 | Austria | See Plans and Pricing | PRODUCT NAME: VEMURAFENIB UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; REGISTRATION NO/DATE: EU/1/12/751/001 (MITTEILUNG) 20120221 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.